Avodart Related Published Studies
Well-designed clinical trials related to Avodart (Dutasteride)
Systematic review evaluating cardiovascular events of the 5-alpha reductase
inhibitor - Dutasteride. [2013]
Efficacy and safety of dutasteride in chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. [2012.01.01]
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. [2011.10]
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. [2011.09]
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). [2011.08]
Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. [2011.07]
The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. [2011.05]
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. [2011.03]
Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study. [2011.03]
Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. [2011.02]
Oral testosterone with and without concomitant inhibition of 5alpha-reductase by dutasteride in hypogonadal men for 28 days. [2011.02]
Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. [2011.02]
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. [2011.01]
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in
the REDUCE study. [2011]
[The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia]. [2010.12]
Comparative effect of finasteride and dutasteride on chromogranin A levels. [2010.11]
Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202. [2010.08]
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. [2010.08]
Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing. [2010.06]
Effect of dutasteride on the risk of prostate cancer. [2010.04.01]
Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. [2010.04]
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. [2010.01]
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male
patients with male pattern hair loss: a randomized, double-blind,
placebo-controlled, phase III study. [2010]
Prostate needle biopsy quality in reduction by dutasteride of prostate cancer
events study: worldwide comparison of improvement with investigator training and
centralized laboratory processing. [2010]
Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. [2009.11.01]
The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial). [2009.11]
The Effect of Dutasteride on the Efficacy of Photoselective Vaporization of the Prostate: Results of a Randomized, Placebo-controlled, Double-blind Study (DOP Trial). [2009.10.01]
[Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study] [2009.04]
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. [2009.04]
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study. [2009.03]
Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. [2009]
Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. [2009]
The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. [2009]
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. [2008.07]
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. [2008.06]
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. [2008.02]
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. [2007.05]
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. [2007.04]
Dutasteride improves male pattern hair loss in a randomized study in identical twins. [2007.03]
The Effect of 5{alpha}-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. [2007.02.13]
The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. [2007]
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. [2006.12]
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study. [2006.11.01]
Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. [2006.09]
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. [2006.05]
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. [2006.04]
Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. [2006.01]
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. [2006]
Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. [2005.05]
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. [2005.01]
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. [2004.10]
Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. [2004.10]
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. [2004.09]
Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia. [2004.08]
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. [2004.05]
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. [2004.04]
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. [2003.10]
Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. [2003.08]
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. [2002.09]
The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. [1999.01]
Well-designed clinical trials possibly related to Avodart (Dutasteride)
Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study. [2014]
Predictors of pathological progression among men with localized prostate cancer
undergoing active surveillance: a sub-analysis of the REDEEM study. [2013]
Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory? [2011.07]
Low serum testosterone levels are poor predictors of sexual dysfunction. [2011.07]
5-alpha-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. [2010.11]
Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion. [2010.06]
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. [2009.04]
Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. [2009.03]
Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. [2009]
Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men. [2005.10]
Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. [2005.01]
The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. [2004.08]
Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors. [1999.08]
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. [1998.12]
Other research related to Avodart (Dutasteride)
Metabolic syndrome-like components and prostate cancer risk: results from the
Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. [2015]
MAPPED study design: a 6 month randomised controlled study to evaluate the effect
of dutasteride on prostate cancer volume using magnetic resonance imaging. [2013]
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer
in men treated with dutasteride: lessons from the REDUCE study. [2012]
The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. [2011.12]
The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. [2011.11]
Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. [2011.09.01]
Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. [2011.08]
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. [2011.06.23]
Development and characterization of dutasteride bearing liposomal systems for topical use. [2011.06.01]
Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian
men: the results from the REDUCE study. [2011]
Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. [2010.10]
Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results. [2010.10]
PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial. [2010.09.15]
Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study. [2010.08.25]
Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group. N Engl J Med 2010;362:1192-202. [2010.08]
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. [2010.07]
Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. [2010.05]
[The effects of dutasteride on voiding and storage symptoms in men with benign
prostatic hyperplasia]. [Article in Japanese] [2010]
Comparative effect of finasteride and dutasteride on chromogranin A levels. [2010]
Effect of dutasteride, tamsulosin and the combination on patient-reported quality
of life and treatment satisfaction in men with moderate-to-severe benign
prostatic hyperplasia: 4-year data from the CombAT study. [2010]
Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone
and body mass index in men with benign prostatic hyperplasia. [2010]
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. [2009.10]
Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. [2009.09.29]
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. [2009.09.19]
Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. [2009.09]
Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. [2009.08.09]
Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. [2009.06]
|
